BioLineRx to Report Annual 2016 Results on March 23, 2017

TEL AVIV, Israel, March 16, 2017

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its audited annual financial results for the year ended December 31, 2016 on Thursday, March 23, 2017, before the US markets open.

The Company will host a conference call on Thursday, March 23, 2017 at 9:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer, and David Malek, Chief Business Officer. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx's website, http://www.biolinerx.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

To dial into the conference call, please dial 1-888-281-1167 from the U.S. or +972-3-918-0687 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call at http://www.biolinerx.com. A dial-in replay of the call will be available until March 26, 2017; please dial 1-888-782-4291 from the U.S. or +972-3-925-5940 internationally.

About BioLineRx 

BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML and is in the midst of a Phase 2b study as an AML consolidation treatment and a Phase 2 study in stem cell mobilization for allogeneic transplantation; and BL-7010 for celiac disease and gluten sensitivity, which has successfully completed a Phase 1/2 study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates; a collaboration agreement with MSD (known as Merck in the US and Canada), on the basis of which the Company has initiated a Phase 2a study in pancreatic cancer using the combination of BL-8040 and Merck's KEYTRUDA^®; and a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 and Genentech's Atezolizumab in several Phase 1b studies for multiple solid tumor indications and AML.